Heckmayr M, Gatzemeier U
Pneumologisch-onkologische Abteilung, Krankenhaus Grosshansdorf, FRG.
Onkologie. 1990 Aug;13(4):285-7. doi: 10.1159/000216777.
Megestrol acetate, a semisynthetic gestagen, is effective not only for endocrine therapy of advanced breast carcinoma, but also in treatment of cachectic patients with aggressive, hormone-independent tumors. 40 patients with therapy-resistant, advanced bronchogenic carcinoma of different histologic type, who had lost more than ten percent of their regular body weight within a prospective, non-randomized trial were treated with megestrol acetate at a dose of either 160 mg/day or 480 mg/day for 3-4 months. The average weight gain of all patients was 3.0 kg. Nearly all of them (80%) reported improved appetite and well-being. The weight gain in the group of patients receiving 160 mg/day was higher (80%) than in the group receiving 480 mg/day (50%), suggesting that the lower dose is as effective as the higher one for palliative treatment.
醋酸甲地孕酮是一种半合成孕激素，不仅对晚期乳腺癌的内分泌治疗有效，而且对患有侵袭性、激素非依赖性肿瘤的恶病质患者也有治疗作用。在一项前瞻性、非随机试验中，40例不同组织学类型的治疗抵抗性晚期支气管癌患者，体重减轻超过正常体重10%，接受了剂量为160毫克/天或480毫克/天的醋酸甲地孕酮治疗，为期3至4个月。所有患者的平均体重增加了3.0千克。几乎所有患者（80%）都表示食欲和健康状况有所改善。接受160毫克/天治疗的患者组体重增加率（80%）高于接受480毫克/天治疗的患者组（50%），这表明较低剂量在姑息治疗中与较高剂量一样有效。
